Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatelizumab long-term follow-up in MS
NCT02306811Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Feb 2015
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of vatelizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Sanofi. Started Feb 2015; status: terminated.
02
Drugs
vatelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02306811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02306811.